RESEARCH ARTICLE

Zika antiviral chemotherapy: identification of drugs and promising starting points for drug discovery from an FDA-approved library [version 1; peer review: 2 approved]

Bruno S. Pascoalino^{1,4}, Gilles Courtemanche², Marli T. Cordeiro³,
Laura H. V. G. Gil³, Lucio H. Freitas-Junior ^{1,4}

¹Laboratório Nacional de Biotecnologias, Centro Nacional de Pesquisa em Energia e Materiais, Campinas-SP, 10000, Brazil

²BIOASTER, Paris, 75015, France

³Centro de Pesquisas Aggeu Magalhães, Fundação Oswaldo Cruz - Fiocruz, Recife/PE, Brazil

⁴Present Address: Instituto Butantan, São Paulo-SP, 1500, Brazil

V1 First published: 14 Oct 2016, 5:2523
<https://doi.org/10.12688/f1000research.9648.1>
Latest published: 14 Oct 2016, 5:2523
<https://doi.org/10.12688/f1000research.9648.1>

Abstract

Background

The recent epidemics of Zika virus (ZIKV) implicated it as the cause of serious and potentially lethal congenital conditions such microcephaly and other central nervous system defects, as well as the development of the Guillain-Barré syndrome in otherwise healthy patients. Recent findings showed that anti-Dengue antibodies are capable of amplifying ZIKV infection by a mechanism similar to antibody-dependent enhancement, increasing the severity of the disease. This scenario becomes potentially catastrophic when the global burden of Dengue and the advent of the newly approved anti-Dengue vaccines in the near future are taken into account. Thus, antiviral chemotherapy should be pursued as a priority strategy to control the spread of the virus and prevent the complications associated with Zika.

Methods

Here we describe a fast and reliable cell-based, high-content screening assay for discovery of anti-ZIKV compounds. This methodology has been used to screen the National Institute of Health Clinical Collection compound library, a small collection of FDA-approved drugs.

Results and conclusion

From 725 FDA-approved compounds triaged, 29 (4%) were found to have anti-Zika virus activity, of which 22 had confirmed (76% of confirmation) by dose-response curves. Five candidates presented selective activity against ZIKV infection and replication in a human cell line. These hits have a broad spectrum of chemotypes and therapeutic uses, offering valuable opportunities for selection of leads for antiviral drug discovery.

Open Peer Review

Approval Status

	1	2
version 1
14 Oct 2016	view	view
1. Paul S Anderson , Independent Pharmaceuticals Professional, Lansdale, USA		
2. Tom von Geldern , Embedded Consulting, Illinois, USA		
Any reports and responses or comments on the article can be found at the end of the article.		

Keywords

Zika, High content screening drug discovery, FDA-approved drugs

This article is included in the **Emerging Diseases and Outbreaks** gateway.

Corresponding author: Lucio H. Freitas-Junior (luciofreitasjunior@gmail.com)

Competing interests: No competing interests were disclosed.

Grant information: This work has been funded by the Sao Paulo State Research Foundation - FAPESP (Process no. 2014/001162-7) and by the National Center for Research on Energy and Materials (CNPEM).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2016 Pascoalino BS *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the [Creative Commons Zero "No rights reserved" data waiver](#) (CC0 1.0 Public domain dedication).

How to cite this article: Pascoalino BS, Courtemanche G, Cordeiro MT *et al.* **Zika antiviral chemotherapy: identification of drugs and promising starting points for drug discovery from an FDA-approved library [version 1; peer review: 2 approved]** F1000Research 2016, 5:2523 <https://doi.org/10.12688/f1000research.9648.1>

First published: 14 Oct 2016, 5:2523 <https://doi.org/10.12688/f1000research.9648.1>

Introduction

Zika virus (ZIKV) is a mosquito-borne virus transmitted by *Aedes* sp. mosquitoes across tropical and subtropical regions around the world. It is a positive single strand RNA flavivirus responsible for, in most of cases, asymptomatic infections. The most common symptoms of Zika are very similar to Dengue fever including headache, muscle and joint pain, mild fever, rash, and inflammation of the underside of the eyelid¹ and, given the commonality of such symptoms, the diagnose is usually imprecise. The virus was first reported in Uganda in 1947 and 60 years after its discovery, only 15 cases were documented until the start of the current epidemics in Americas, mainly in Brazil². Although ZIKV was first isolated nearly 70 years ago, very little is known about the virus biology, as most of the cases likely remained unreported and the transmission had been sporadic and silent for most of time³.

The Latin America Zika epidemic drew attention especially due to the related cases of microcephaly. Since 2014, the number of microcephaly cases in Brazil increased 20 times and its incidence overlapped with Zika epidemic areas². Moreover, recent work has demonstrated that Zika infection impairs the growth of neurospheres⁴ and causes birth defects in mice⁵, indicating the virus influence in the fetal development. Although the more recent Zika outbreaks suggests that *Aedes aegypti* is the main vector, it has been shown that other mosquito species are capable of carrying and thus possibly transmitting the virus⁶ – for example, ZIKV was isolated from the ubiquitous *Culex* species, which is also present in countries of milder climates. But the importance of this mosquito as a potential disease vector is still not understood³. Furthermore, sexual transmission of Zika virus was already reported in temperate countries without mosquito vectors⁶ suggesting that Zika transmission could eventually be established outside tropical areas.

Recent studies call attention for the risk of pre-immunity to Dengue leading to complications during Zika. Anti-Dengue antibodies could enhance the infection in Zika⁷, most likely by a mechanism known as antibody-dependent enhancement (ADE), which is also the pathophysiological mechanism that causes severe Dengue. The Dengue epidemics persists in the tropical and sub-tropical areas around the globe, and combined with the upcoming introduction of newly developed anti-Dengue vaccines^{8,9}, it could lead to a potentially catastrophic scenario when Zika complications due to ADE are considered. For this reason, vaccines should not be the only control strategy to pursue against epidemic flaviviruses. Efforts must be focused in the development of novel approaches to control the pathogens, instead of just depending on the vector control and palliative care to ease the disease symptoms.

High content screening (HCS) was recently used for discovery of inhibitors of Dengue virus (DENV) and Chikungunya virus (CHIKV) infection^{10,11}. This is a cell-based and innovative image-based assay using libraries of small molecules against the viruses to identify compounds that possess antiviral activity during infection of a human host cell. The advantage of HCS over others High-throughput screening (HTS) assays (such as target-based) is that the amount of information that can be generated from images of a single treatment is not limited to a single value. Aside from

the degree of viral infection and cell viability, other relevant information can be extracted from images such as morphological changes in host cell, protein localization, among others¹². Another advantage is that HCS precludes the need for a validated target, as compounds can be screened against all putative molecular targets at a single experiment, in a physiologically relevant condition. This condition becomes a considerable advantage in the case of Zika, in which both viral and host targets remain to be discovered. Thus, cell-based screening is a viable strategy to rapidly advance drug discovery for Zika.

Drug repurposing is a well-known strategy by the pharmaceutical industry, that speeds-up the drug discovery process. Also known as drug repositioning, it is basically the use of known drugs or compounds to treat new indications. The obvious advantage of drug repurposing over the traditional drug development is the gain in time and the lower costs, since the repurposed drug has already been approved for clinical use. For this reason, in addition to quickly enabling the start of clinical trials for a different therapeutic use, the risk of failure due to adverse toxicology is greatly reduced. Besides drug repurposing, these compounds can also serve as starting material for the development of leads for new therapeutic purposes.

Here we describe a high content screening methodology for the discovery of inhibitors of ZIKV infection applied in a drug repurposing context. This assay was used to screen a library of FDA-approved drugs, resulting in the identification of five compounds with selective activity against ZIKV in human cells.

Methods

Zika virus (ZIKV)

The Zika virus (KX197192.1) used in this project was isolated from a patient in Pernambuco-Brazil in 2015.

Huh7

The human hepatome cell Huh7 (JCRB0403), obtained from the Japanese Cell Bank, was cultivated in DMEM F-12 media (Sigma-Aldrich) supplemented with 10% fetal bovine serum (FBS) (Sigma-Aldrich), 100 units/mL of Penicillin and 100 µg/mL of Streptomycin (Sigma-Aldrich), at 37°C, 5% CO₂.

C636

The *Aedes albopictus* cell C636, kindly provided by Dr. Amílcar Tanuri from Universidade Federal do Rio de Janeiro, was cultivated in Leibovitz L-15 media (Sigma-Aldrich) supplemented with 10% FBS (Sigma-Aldrich), 0.26% tryptose phosphate (Sigma-Aldrich), 100 units/mL of Penicillin and 100 µg/mL of Streptomycin (Sigma-Aldrich), at 28°C¹³.

Hybridoma cells D1-4G2-4-15 (HB-112)

The mouse hybridoma cells D1-4G2-4-15 (HB-112), obtained from Rio de Janeiro Cell Bank, was cultivated in DMEM F-12 media (Sigma-Aldrich), supplemented with 10% FBS (Sigma-Aldrich), 100 units/mL of Penicillin and 100 µg/mL of Streptomycin (Sigma-Aldrich), at 37°C, 5% CO₂. Exponentially growing hybridoma cells were used to produce ascitic fluid as described by Yokoyama *et al.*¹⁴.

Viral propagation and quantification

Zika viruses were used to infect C636 cells at 80% confluency at a multiplicity of infection (MOI) of 0.01 for 96 h. The supernatant was harvested, aliquoted in sterile conical tubes and frozen at -80°C. The obtained viruses were quantified by plaque assay using Huh7 cells, as described for Dengue virus by Medina *et al.*¹⁵.

Compound libraries and reference compound

The NIH Clinical Collection compound library (Evotec) was used. The human recombinant Interferon α 2A (Sigma-Aldrich) was used as reference compound. The compounds were diluted in 100% dimethylsulfoxide (DMSO) (Sigma-Aldrich), with the exception of IFN α 2A (Thermo Scientific) that was prepared in Dulbecco's Phosphate-buffered saline (DPBS) (Sigma-Aldrich) containing 0.5% (W/V) bovine albumin (Sigma-Aldrich).

ZIKV compound screening assay

The NIH Clinical Collection compound library (Evotec) was screened against ZIKV at 20 μ M in 1% DMSO. MOCK-infected Huh7 and IFN α 2A (1.55 nM) were used as positive controls, and the 1% DMSO (vehicle)-treated cells were used as negative control. In each run, a 10-point dose-response curve of the reference compound IFN α 2A, starting at 1.55 nM and diluted in a factor of 2, was also used for assay quality control. The compounds were diluted 16.6 $\times$ in DPBS 1 $\times$ in the μ Clear Black 384-well plates (Greiner Bio-One) for a final volume of 10 μ L of compound at 6% DMSO. After that, 50 μ L of a mixture of Huh7 cells at 6 $\times$ 10⁴ cells/mL and ZIKV at a MOI of 0.5, were added in each well of the plate resulting in a final concentration of 1% DMSO and a final volume of 60 μ L/well. After 72 h of incubation at 37°C and 5% CO₂, the cells were submitted to indirect immunofluorescence (IF) protocol as described below. The primary screening was performed in two independent experiments and the confirmation ratio was calculated by the number of common hits in both assays divided by the total number of hits of the first assay using Pearson test in Graphpad Prism software, version 6. Scatter-plot distribution of the entire screening was generated using Spotfire 7.0 (TIBCO).

Detection of infected cells by indirect immunofluorescence

The Huh7 cells were fixed with 4% (w/v) (PFA) (Sigma-Aldrich) for 30 min at room temperature, treated with 0.25% (v/v) Triton-X for 15 min and incubated with the primary monoclonal antibody D1-4G2-4-15 (HB-112) prepared in DPBS containing 2.5% FBS at 37°C for 2 h. After two wash steps with DPBS, plates were incubated with AlexaFluor594 conjugated goat anti-mouse IgG (Thermo Scientific) and 5 μ g/mL of DAPI (4, 6 diamidino-2-phenylindole) (Sigma-Aldrich) in DPBS at 37°C temperature for 1 h, and then washed again twice with DPBS. After the final washing, digital images were acquired using a high content imaging system, the Operetta (Perkin Elmer). The digital images were taken from four different fields of each well at 20 $\times$ magnification.

Data normalization and assay quality control

The acquired images were analyzed with the High Content Analysis (HCA) software Columbus (Perkin Elmer) for identification, segmentation and quantification of host cell nucleus, cytoplasm and intracellular virus labeling with the specific antibody

(Figure 1). The HCA provides as output data for all images from one well the total number of cells and total number of infected cells. For the purpose of this study, the infection ratio (IR) was defined as the ratio between the total number of infected cells in all images from the well and the total number of cells in all images from the same well. The raw data for IR values were normalized to negative (infected cells, DMSO-treated) and positive controls (infected cells treated with Interferon α 2A at a concentration of 1.55 nM) to determine the normalized antiviral activity, according to the equation below:

$$(i) \text{ Normalized Activity (NA)} = [1 - (\text{Av. IRN} - \text{Av. IRT}) / \text{Av. IRN} - \text{Av. IRP}] \times 100$$

where:

Av. IRN: average infection ratio of negative control wells

Av. IRP: average infection ratio of positive control wells

Av. IRT: average infection ratio of test compound wells (in a given concentration)

NA values of the reference compound dose-response curve were processed with the Graphpad Prism software, version 6, for generation of sigmoidal dose-response (variable slope) non-linear curve fitting and determination of the EC₅₀ values, defined as the effective concentration resulting in a 50% inhibition of ZIKV infection. The statistical validity of the Zika virus high content screening was determined by calculating the Z'-factor²⁷ using the infected Huh7 treated with 1% DMSO or IFN α 2A as negative and positive controls, respectively. As quality control of the screenings, a 1% DMSO plate and two IFN α 2A dose-response curve plates were performed in each run (Figure 2).

Hit selection criteria

Were considered as hits, compounds that presented both normalized activity (see formula above) and cell ratio (number of cells of the tested compound divided by the mean of 1% DMSO-treated cells) equal or superior of 50%.

Activity confirmation in dose-response curves

To confirm the compound activity against Zika viruses, the selected hits from both primary screenings were tested in a 9 point DRC, with 2-fold serial dilutions starting at 50 μ M, using the same assay and data analysis described for the primary screening. The EC₅₀ value was used to evaluate compound activity. The CC₅₀ value, defined as the compound concentration resulting in a 50% reduction in cell viability compared with the infected IFN α 2A treated cells, was used to evaluate cell toxicity. The compounds that presented the Selectivity Index (SI), which is calculated as $SI = CC_{50} / EC_{50}$, equal or higher than 1 and that reached at least 50% of maximum activity were considered as confirmed hits. Here we describe a high content screening methodology for the discovery of inhibitors of ZIKV infection applied in a drug repurposing context. This assay was used to screen a library of FDA-approved drugs, resulting in the identification of five compounds with selective activity against ZIKV in human cells.

Figure 2. Plate map of the control plates used during the campaign. Upper panel represents the 1% DMSO plate, control of the variability among the wells of the plate. Lower panel represents the dose-response of the reference compound Interferon α 2A, which serves as control of the entire run, where: 1% DMSO vehicle treated ZIKV infected cells (blue), representing the samples; 1.5 nM IFN α 2A treated ZIKV infected cells (positive control) (green); Mock infected cells (red); 1% DMSO treated ZIKV infected cells (negative control) (grey).

Results

Assay development

The first step to develop the high content Zika virus screening assay was to adapt the ZIKV to infect a suitable cell line, in this case the human cell line Huh7, in 384-well plates. The optimal cell density, virus MOI and necessary period of time for the efficient viral infection in the host cell were determined. For this purpose the Huh7 cells were seeded in four different densities (2×10^4 , 4×10^4 , 6×10^4 and 8×10^4 cells/mL), combined with three different MOI (0.25, 0.5 and 1) for 2, 3 or 4 days, using mock-infected Huh7 cells as controls. At the assay endpoint, all conditions were submitted to indirect immunofluorescence using as primary antibody the monoclonal mAb 4G2, which recognizes the E protein of flaviviruses, to detect the infected cells. Images were randomly acquired from all conditions and submitted to High Content Analysis for the determination of the infected and non-infected cells populations, followed by the determination of the infection ratio (ratio of infected cells to the total number of cells) and the cytotoxicity. Figure 1 shows a representation of the methodology employed to detect the viral infection in host cells. After analyzing the data, the cell density of 6×10^4 cells/mL, MOI = 0.5 and 72 h of infection were selected as the best conditions for virus infection (Table S1), presenting the highest infection ratio, varying from 60–90% and cell ratio combined with lowest variation of infection in 384 plates, with a coefficient of variation below 10%.

Human α Interferon 2A as reference compound and assay validation

The Interferon α 2A was previously reported to have anti-flaviviral activity^{16,17} and, for this reason it was chosen as the reference compound in this assay. The antiviral activity of IFN α 2A in ZIKV-infected Huh7 cells was verified in dose-response curves and. After 72 h, the infection level was determined by indirect immunofluorescence (IF) and the extracted data were analyzed

and used to plot a sigmoidal dose-response curve (Figure 3). The EC_{50} of 2.07 pM and the minimal effective concentration (capable of eradicating the infection) of 1.5 nM were determined for IFN α 2A against ZIKV. As can be observed in Figure 3, IFN α 2A activity can also protect against the ZIKV cytopathic effect, which leads to cell lysis; thus, the ratio between the number of cells in treated wells and the number of cells in non-treated wells (defined as the cell ratio) increases in dose-dependent manner to the concentration of IFN α 2A, indicating the interferon capacity of protecting the host cells from lysis due to ZIKV infection.

The final step of the assay validation was the evaluation of the Z'-factor¹⁸ for ZIKV infection in Huh7 using IFN α 2A as the reference compound. Figure 4A shows a representation of the assay performed, where cells viruses and the reference compound were dispensed following the designed 384-well plate template. The assay resultant data were used to generate a scatter plot and a Z'-factor¹⁸ of 0.63 was obtained (Figure 4B).

Screening of the NIH clinical collection compounds library

The screened library consisted of 725 compounds from a collection of chemically diverse FDA-approved drugs with known and unknown mechanisms of action. The entire library was screened at 20 μ M against ZIKV infecting Huh7 cells, using IFN α 2A at 1.5 nM as the reference drug and 1% DMSO (vehicle)-treated infected cells as negative controls. As quality control of the assay, two dose-response curves of the reference compound and a 1% DMSO plate were performed (Figure 2). The library was screened in two independent experiments, and the correlation coefficient (R) of 0.81 obtained, which was determined for the normalized activity of each compound between the first (R1) and the second (R2) screens, including compounds and controls (Figure S1). The mean Z'-factor of the screenings were 0.74 ± 0.06 for R1, and 0.56 ± 0.09 for R2 (Figure 5). Out of 725 triaged compounds, 12 and

Figure 3. Dose-dependent activity of Interferon α 2A (IFN α 2A) against Zika infection. ZIKV infected cells were treated with different doses of IFN α 2A in a dose-response curve. After 72 h of incubation the cells were submitted to indirect immunofluorescence assay and the infection ratio determined. The data was normalized with the controls and the resultant normalized activity used to plot a sigmoidal dose-response curve (variable slope). The effective concentration resulting in a 50% inhibition of ZIKV infection (EC_{50}) of 2.07 pM was obtained and the concentration of 1.5 nM defined as the effective concentration (capable of eradicating the infection). The cell ratio (number of cells of the tested compound divided by the mean of 1% DMSO-treated cells) is represented in red and the normalized activity in black.

Figure 5. Activity profile of the NIH Clinical Collection library anti-Zika virus high content primary screening. In two independent runs, the compounds selected as hits (normalized activity $\geq 50\%$ and cell ratio ≥ 0.5) are located in the right superior quadrant. Dots represent each single tested well and colors represent different treatments, where: ZIKV infected cells treated with different compound samples (blue); 1.5 nM IFN α 2A treated ZIKV infected cells (positive control) (green); Vehicle DMSO 1% treated mock infected cells (red); 1% DMSO treated ZIKV infected cells (negative control) (grey). The table in the right summarizes the results obtained both runs.

Recently, Palonosetron anti-ZIKV activity was also verified in an assay similar to the described in this work²².

Dataset 1. Raw data of 'identification of drugs and promising starting points for drug discovery from an FDA-approved library'

<http://dx.doi.org/10.5256/f1000research.9648.d137642>

The raw data supporting the findings described in the paper are provided.

Discussion

The advent of Zika virus infections and its fast spreading across the globe, together with reported association of the ZIKV with severe birth defects, including microcephaly and Guillain-Barré syndrome, has raised attention for the importance of searching for mechanisms of control the disease that go beyond vector surveillance and palliative supporting treatment to ease symptoms. Although the exact causes of microcephaly are still unknown, new data suggest that it may be caused by intrauterine infection during the development of the brain^{23–26}. Additionally, other studies have

shown in animal models that ZIKV is able to infect the placenta and cross it to infect the fetal brain^{5,27,28}.

Recent data from World Health Organization reported that in the last years 61 countries and territories presented mosquito-borne transmission of Zika. From these, 13 countries or territories described cases of microcephaly and other central nervous system malformations potentially associated with Zika virus infection. In addition, studies from 10 different countries have reported evidence of person-to-person transmission of Zika virus, probably via a sexual route²⁹, indicating that Zika may not be restricted only to the tropical and sub-tropical areas where the mosquitoes of the genus *Aedes* sp. is found.

New studies demonstrated that plasma immune to Dengue viruses showed substantial cross-reaction to ZIKV, including being capable to initiate ADE of ZIKV infection⁷, which could, at least partially, explain the huge increment in the number of reported Zika virus infections after Dengue outbreaks and in areas where Dengue virus is prevalent. Moreover, this cross-reactivity of the anti-Dengue sera with Zika viruses could be a risk point for the newly developed anti-Dengue vaccines^{8,9}.

In the present work, we developed a fast, robust and reliable technology of high content screening assay for Zika virus. This novel methodology identified five promising compounds (Table 2), among 725 FDA-approved compounds from the NIH Clinical Collection compound library. Two of these compounds were previously described as having anti-ZIKV activity. The 6-Azauridine, which has been reported to have anti-flaviviral activity against 11 members of the flaviviral family, including Zika virus¹⁷, and Palonosetron in a similar assay described in this work²². In fact, the detection of hit compounds with previously described anti-ZIKV activity in the screened library validates this approach and demonstrates that the assay is useful for the discovery of novel compounds capable of inhibiting ZIKV infection. It also reinforces that these compounds have promising activity against ZIKV and were able to stand scrutiny of two different screening assays. Conversely, compounds that were recently reported with anti-ZIKV activity³⁰ such as Azathioprine, Dactinomycin, Digoxin, Mebendazole and Mefloquine, presented toxicity higher than 50% in our assay and Clofazimine, Mercaptopurine, Methoxsalen and Sertraline-HCl, which presented activity lower than 50% in our assay. This suggests that these compounds might have a narrow spectrum of activity against some but not all ZIKV isolates. Furthermore, the assay here described is also capable of identifying slowly acting drugs, which demand extended exposure to manifest their effect.

The clear advantage of this screening is the fact that the assay covers the viral entry, RNA synthesis and viral egress of the host cell, since the Huh7 are exposed to Zika virus for 72 h, respecting the viral biology during the infection of the host.

All the five herein identified active compounds are currently marketed drugs for distinct treatments. The molecular structure and pharmacokinetics data of the compounds are summarized in Table 1 and Table 2. Lovastatin belongs to the family of statins, which are widely used for lowering cholesterol in patients with

hypercholesterolemia, to reduce risk of cardiovascular disease. A clinical trial tested the efficacy of the treatment of Dengue-infected patients with Lovastatin³¹, since the endothelial stabilizing effects of statins could decrease Dengue-related vasculopathy. Although Lovastatin anti-flaviviral activity was already reported in hepatitis C virus³² and Dengue virus^{33,34}, no evidence of a beneficial effect on any of the clinical manifestations or on Dengue viremia was found. In addition, Lovastatin was reported to attenuate nervous injury in animal model of Guillain-Barré syndrome³⁵.

5-Fluorouracil is a product of the metabolism of floxuridine, a drug long used in the treatment of diverse types of cancer³⁶. It belongs to a drug class known as antimetabolites, and is a pyrimidine analog that irreversibly inhibits thymidylate synthase, impairing the DNA synthesis. The anti-flaviviral activity of Floxuridine against Dengue and West Nile virus was already reported^{37,38}, and here we demonstrate that it also has activity against Zika virus.

6-Azauridine is generally administrated as the triacetylated prodrug, Azaribine. 6-Azauridine, is an antimetabolite capable to inhibit both DNA and RNA virus multiplication. 6-Azauridine was withdrawn from clinical use because of the occurrence of arterial and venous thromboembolic episodes in some psoriatic patients³⁹. Early work demonstrated that viruses sensible to 6-Azauridine induced increased levels of uridine kinase, which converts uridine to uridine monophosphate, a nucleotide used in RNA synthesis, that could explain the activity of the 6-Azauridine on such viruses⁴⁰. More recently, 6-Azauridine was reported to have a broad activity against 11 flaviviruses, including Zika¹⁷.

Kitasamycin is a natural product from *Streptomyces narbonensis* that belongs to the macrolide antibiotic class. The compound is a broad spectrum antimicrobial drug against several pathogens, such as Gram positive bacteria, mycoplasma and leptospira. This macrolide binds to bacterial ribosomal RNA and inhibits protein biosynthesis⁴¹. Although Kitasamycin is clinically used, this is the first time, to our knowledge, that it has been reported to have antiviral activity.

Palonosetron is a 5-HT₃ serotonin receptor antagonist used for preventing nausea and vomiting induced by chemotherapeutic agents. Palonosetron anti-ZIKV activity was also reported in a recent work²².

Taking a closer look at the selected compounds, they clearly do not belong to the same class of molecules since their structures are quite different (Table 1). Moreover, the calculated properties of the molecules also vary widely (Table 2). Regarding the molecule size, 5-Fluorouracil and 6-Azauridine can be considered small, Palonosetron and Lovastatin are medium-sized while Kitasamycin is a big compound, in terms of drugs. 5-Fluorouracil and 6-Azauridine are hydrophilic while Palonosetron, Lovastatin and Kitasamycin are more lipophilic. 5-Fluorouracil, Lovastatin and Palonosetron have few H bond acceptors and donors, while 6-Azauridine and Kitasamycin have several. Finally, 6-Azauridine and Kitasamycin have a high topological polar surface area (TPSA) while Lovastatin, 5-Fluorouracil and Palonosetron have a low topological polar surface area, compatible with potential brain penetration, which could be a very important feature since the

Table 1. Molecular structure and dose-response curve of the five most promising compounds identified in the anti-Zika virus high content screening of the NIH Clinical Collection library.

Chemical Name	Structure	Dose-response curve
Lovastatin
5-Fluorouracil
6-Azauridine
Palonosetron
Kitasamycin

viral infection causes severe damage in the nervous systems under development. These calculated properties allow anticipating very different physico-chemical properties of these hits, likely resulting in very different absorption, distribution, metabolization and excretion profiles for these molecules. These profiles could be considered as advantages or drawbacks in a potential antiviral treatment depending on the target product profile of a Zika treatment and should be used to prioritize these chemotypes for further screening campaigns.

These compounds showed specific activity against a ZIKV isolate originated in Pernambuco-Brazil, one of the states with the highest number of microcephaly and other newborn nervous system malformations reported cases⁴².

The drugs here described can serve as important starting points for the development of analogs or new molecules for the treatment of Zika. Searching for structural analogs of the five molecules, 4,449 similar structures were identified in Pubchem (Table S3). Screening these analogs could help gaining knowledge on the structure-activity relationship (SAR), an important step on medicinal chemistry optimization of a lead compound. Moreover, 10 of these analogs are already marketed drugs (Table S3). We can also consider their historical therapeutic class or mechanism of action as clues to select known chemical entities with similar mechanisms of action to screen against ZIKV. For example, statins or macrolides, widely represented in the pharmacopeia, could be screened in order to identify more potent anti-ZIKV hits. The hits can also be used in target deconvolution studies to identify host molecules

Table 2. Summarized chemical and physical properties of the most promising compounds identified with anti-ZIKV activity.

Drug	Palonosetron	6-Azauridine	5-Fluorouracil	Lovastatin	Kitasamycin
Pubchem CID	6337614	5901	3385	53232	44634697
NIH ID	SAM001246791	SAM001246876	SAM002264615	SAM002589963	SAM001246731
EC ₅₀ (μM)	16.3 ± 7.7	2.3 ± 0.1	14.3 ± 8.6	20.7 ± 8.6	41.7 ± 10.1
CC ₅₀ (μM)	ND	ND	ND	ND	ND
Max. Activity (% of infection inhibition)	97.7	88.3	57	60.7	69.1
S.I. (CC ₅₀ /EC ₅₀)	> 3.06	> 33.33	> 2.5	> 2.5	> 1.2
Water Solubility (mg/mL)	Very high	Very high	12.5	0.0004	0.05
M.W. (g/mol)	296.41	245.19	130.08	404.54	828.00
LogP	2.8	-2.1	-0.9	4.3	2.9
HBD	0	4	2	1	3
HBA	2	7	3	5	16
Rot	1	2	0	7	14
TPSA	23.6	132	58.2	72.8	206

EC ₅₀ (μM)	Max. Activity (% of infection inhibition)	S.I. (CC ₅₀ /EC ₅₀)	Water Solubility (mg/mL)
<10	>90	>10	High
[10–30]	[75–90]	[2–10]	Medium
>30	<75	<2	Low

involved in ZIKV infection as was already described for other viruses like Chikungunya virus⁴³.

Combining the information generated in this study and the pharmaceutical properties available for the best compounds here identified, we considered Palonosetron as the most promising compound. This drug can be dosed either by oral or intravenous route, in humans its bioavailability is very high (97%) and half-life is very long (40h), making it a good candidate for *in vivo* confirmation. However, its metabolism, albeit low, mainly involves cytochrome P450 2D6. As there is a high interindividual variability in the efficiency and amount of CYP2D6 enzyme produced, it can be anticipated that this drug may be subjected to substantial variation when metabolized in humans. This problem could be addressed in a medicinal chemistry lead optimization project, provided that SAR is observed. However, this drawback did not prevent Palonosetron (commercialized by Esai as Aloxi®) to reach the market. Interestingly, other 5-HT₃ antagonists like Dolasetron, Ondansetron, Granisetron, Tropisetron and Alosetron,

discovered by different pharmaceutical companies, with similar or different chemotypes, also reached the market. These compounds, generally developed for treatment of chemotherapy-induced nausea have been widely prescribed (off-label) for morning sickness during pregnancy. The possibility to treat pregnant women with this class of compounds is another advantage in Zika infection, albeit their safety profile for newborns is currently controversial^{44,45}.

In summary, the study developed here describes a high content screening assay which successfully identified five active compounds against Zika virus isolated in an area of high number of reported cases of newborn neural complications. Further investigation is needed to understand the mechanism of action responsible for the inhibition of the Zika virus infection. However, the molecules identified in this study are important starting points, since they can be further optimized to increase the efficiency inhibiting ZIKV infection. Moreover, based on the structure comparison, more than 4000 molecules were identified in the PubChem

databank as analogs and structural variants which could be also be tested, and still more specific and potent compounds can still be identified or even designed.

Data availability

F1000Research: Dataset 1. Raw data of 'identification of drugs and promising starting points for drug discovery from an FDA-approved library', [10.5256/f1000research.9648.d137642](https://doi.org/10.5256/f1000research.9648.d137642)⁴⁶

Author contributions

BSP and LFJ were involved in project design. BSP performed the experiments and data evaluation. GC was responsible for the hit analysis and medicinal chemistry insights. MTC was responsible for isolating and propagating the ZIKV strain used in this study. All the authors contributed with the article writing and agreed with its content.

Competing interests

No competing interests were disclosed.

Grant information

This work has been funded by the Sao Paulo State Research Foundation - FAPESP (Process no. 2014/001162-7) and by the National Center for Research on Energy and Materials (CNPEM).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Acknowledgements

We would like to thank Dr. Amílcar Tanuri for supplying the *Aedes albopictus* C636 cell line and Dr. Carolina B. Moraes for critically reviewing this manuscript. We are also grateful to the National Institute of Health for providing the NIH Clinical Collection compound library used in this work.

Supplementary data

Figure S1. Two independent screenings of the NIH Clinical Collection in the Zika high content assay show a high degree of correlation. Normalized activity of the samples and controls were plotted in Spotfire software (Tibco) and the correlation coefficient (R) of the two runs calculated using Pearson test in GraphPad Prism software. Dots represent each single tested well and colors represent different treatments, where: ZIKV infected cells treated with different compound samples (blue); 1.5 nM IFN α 2A treated ZIKV infected cells (positive control) (green); Vehicle 1% DMSO treated mock infected cells (red); 1% DMSO treated ZIKV infected cells (negative control) (grey).

Table S1. Adaptation of the ZIKV infection in Huh7 hepatoma cells regarding the cell density, multiplicity of infection and infection time.

	48 h				72 h				96 h			
	Cell ratio	Cell ratio SD	Infection Ratio	Infection Ratio SD	Cell ratio	Cell ratio SD	Infection Ratio	Infection Ratio SD	Cell ratio	Cell ratio SD	Infection Ratio	Infection Ratio SD
MOI 0.25												
MOI 0.5												
MOI 1												
Mock infected												
2x10 ⁴ cell/mL	0.675	0.074	0.044	0.018	0.673	0.060	0.206	0.027	0.502	0.057	0.606	0.100
2x10 ⁴ cell/mL	0.862	0.096	0.069	0.029	0.745	0.047	0.240	0.032	0.430	0.069	0.550	0.094
2x10 ⁴ cell/mL	0.587	0.106	0.188	0.092	0.767	0.039	0.259	0.109	0.158	0.048	0.488	0.181
4x10 ⁴ cell/mL	0.873	0.127	0.097	0.046	0.739	0.031	0.271	0.127	0.508	0.079	0.628	0.053
4x10 ⁴ cell/mL	0.909	0.104	0.084	0.027	0.756	0.045	0.392	0.216	0.533	0.066	0.544	0.120
4x10 ⁴ cell/mL	0.997	0.094	0.113	0.039	0.751	0.035	0.550	0.217	0.248	0.086	0.575	0.097
6x10 ⁴ cell/mL	0.974	0.176	0.085	0.022	0.905	0.081	0.780	0.130	0.498	0.060	0.567	0.063
6x10 ⁴ cell/mL	1.059	0.172	0.096	0.029	0.903	0.055	0.836	0.075	0.526	0.035	0.564	0.043
6x10 ⁴ cell/mL	0.839	0.243	0.131	0.171	0.863	0.066	0.800	0.132	0.446	0.061	0.578	0.068
8x10 ⁴ cell/mL	1.038	0.148	0.141	0.039	0.912	0.045	0.548	0.256	0.536	0.048	0.536	0.061
8x10 ⁴ cell/mL	1.065	0.136	0.092	0.031	0.896	0.057	0.537	0.233	0.521	0.038	0.554	0.048
8x10 ⁴ cell/mL	0.926	0.111	0.074	0.038	0.884	0.064	0.430	0.249	0.505	0.029	0.560	0.045

Table S2. Summarized information of the identified compounds in the primary screening of the NIH Clinical Collection library not selected for further analysis.

NIH ID#	EC ₅₀ (μM)	CC ₅₀ (μM)	Max. Activity (%)	SI
SAM002589981	22 ± 8	38.3 ± 8.7	101.7	1.74
SAM002564206	14.7 ± 4.2	21.3 ± 12.3	98.5	1.87
SAM002564189	19.3 ± 5.5	11.7 ± 11	88.9	0.6
SAM002554886	14.7 ± 3.1	34 ± 11.3	76.1	3.01
SAM002548975	12.3 ± 5.7	43.7 ± 9.3	92.9	3.54
SAM002548938	21.3 ± 10	31.3 ± 15.3	96.6	1.47
SAM002264636	19.7 ± 4.5	28.3 ± 17.6	87.1	1.44
SAM001247107	14 ± 0	19.3 ± 9.7	92.2	1.38
SAM001247103	8 ± 2.6	8 ± 3	101.7	1
SAM001247083	21.5 ± 0.7	16.5	68.5	1.34
SAM001247075	12 ± 1.7	33.7 ± 10.8	95.6	2.8
SAM001247056	14.3 ± 3.5	8.7 ± 1.2	99.8	0.6
SAM001247054	10.3 ± 3.1	9 ± 4.4	101.7	0.87
SAM001247052	9.7 ± 1.5	14.7 ± 2.5	92.6	1.51
SAM001247038	17.3 ± 4.9	31.3 ± 15	88.8	1.8
SAM001246989	15.3 ± 5.8	13.3 ± 7.6	101.7	0.87
SAM001246979	17 ± 4.2	23.5 ± 13.6	68.9	1.38
SAM001246977	17 ± 3.6	24.3 ± 3.1	101.3	1.43
SAM001246883	13 ± 1	32 ± 14	83.6	2.46
SAM001246690	14.5 ± 0.7	26.5 ± 0.7	95.1	1.82
SAM001246686	ND	ND	69.7	ND
SAM001246644	5.3 ± 1.5	29 ± 2	72	5.44
SAM001246622	13.3 ± 5.8	20.3 ± 2.9	90.2	1.75
SAM001246545	10.7 ± 2.1	20.7 ± 4.1	88.7	1.94

Table S3. Analogs compounds and Medications of the compounds identified with anti-ZIKV activity.

INN	Pubchem CID	Analogs in Pubchem	
		Similar compounds	Medications
Lovastatin	53232	2361	Mevastatin
			L669262
			6-Hydroxyisocompactin
			Monacolin J, L, M
			Simvastatin
5-Fluorouracil	3385	71	Wuxistatin
6-Azauridine	5901	127	Methimazole
			Decitabine
Palonosetron	6337614	419	Cytarabine
Kitasamycin	44634697	1471	none
		4449	Tylosin

References

1. WHO: **Zika virus, Fact Sheets**. 2016.
[Reference Source](#)
2. Fauci AS, Morens DM: **Zika Virus in the Americas--Yet Another Arbovirus Threat**. *N Engl J Med*. 2016; **374**(7): 601–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
3. Musso D, Gubler DJ: **Zika Virus**. *Clin Microbiol Rev*. 2016; **29**(3): 487–524.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
4. Garcez PP, Loliola EC, Madeiro da Costa R, *et al.*: **Zika virus impairs growth in human neurospheres and brain organoids**. *Science*. 2016; **352**(6287): 816–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
5. Cugola FR, Fernandes IR, Russo FB, *et al.*: **The Brazilian Zika virus strain causes birth defects in experimental models**. *Nature*. 2016; **534**(7606): 267–71.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
6. Hills SL, Russell K, Hennessey M, *et al.*: **Transmission of Zika Virus Through Sexual Contact with Travelers to Areas of Ongoing Transmission - Continental United States, 2016**. *MMWR Morb Mortal Wkly Rep*. 2016; **65**(8): 215–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
7. Dejnirattisai W, Supasa P, Wongwiwat W, *et al.*: **Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with Zika virus**. *Nat Immunol*. 2016; **17**(9): 1102–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
8. Capeding MR, Tran NH, Hadinegoro SR, *et al.*: **Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial**. *Lancet*. 2014; **384**(9951): 1358–65.
[PubMed Abstract](#) | [Publisher Full Text](#)
9. Villar L, Dayan GH, Arredondo-García JL, *et al.*: **Efficacy of a tetravalent dengue vaccine in children in Latin America**. *N Engl J Med*. 2015; **372**(2): 113–23.
[PubMed Abstract](#) | [Publisher Full Text](#)
10. Cruz DJ, Koishi AC, Taniguchi JB, *et al.*: **High content screening of a kinase-focused library reveals compounds broadly-active against dengue viruses**. *PLoS Negl Trop Dis*. 2013; **7**(2): e2073.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
11. Cruz DJ, Bonotto RM, Gomes RG, *et al.*: **Identification of novel compounds inhibiting chikungunya virus-induced cell death by high throughput screening of a kinase inhibitor library**. *PLoS Negl Trop Dis*. 2013; **7**(10): e2471.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
12. Götte M, Gabriel D: **Image-Based High-Content Screening in Drug Discovery**. In *Drug Discovery and Development - Present and Future*. DI Kapetanovic, Editor. Intech: Switzerland; 2011.
[Publisher Full Text](#)
13. Igarashi A: **Isolation of a Singh's *Aedes albopictus* cell clone sensitive to Dengue and Chikungunya viruses**. *J Gen Virol*. 1978; **40**(3): 531–44.
[PubMed Abstract](#) | [Publisher Full Text](#)
14. Yokoyama WM: **Production of monoclonal antibody supernatant and ascites fluid**. *Curr Protoc Mol Biol*. 2008; **Chapter 11**: Unit 11.10.
[PubMed Abstract](#) | [Publisher Full Text](#)
15. Medina F, Medina JF, Colón C, *et al.*: **Dengue virus: isolation, propagation, quantification, and storage**. *Curr Protoc Microbiol*. 2012; **Chapter 15**: Unit 15D.2.
[PubMed Abstract](#) | [Publisher Full Text](#)
16. Ajariyakhajorn C, Mammen MP Jr, Endy TP, *et al.*: **Randomized, placebo-controlled trial of nonpegylated and pegylated forms of recombinant human alpha interferon 2a for suppression of dengue virus viremia in rhesus monkeys**. *Antimicrob Agents Chemother*. 2005; **49**(11): 4508–14.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
17. Crance JM, Scaramozzino N, Jouan A, *et al.*: **Interferon, ribavirin, 6-azauridine and glycyrrhizin: antiviral compounds active against pathogenic flaviviruses**. *Antiviral Res*. 2003; **58**(1): 73–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
18. Zhang JH, Chung TD, Oldenburg KR: **A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays**. *J Biomol Screen*. 1999; **4**(2): 67–73.
[PubMed Abstract](#) | [Publisher Full Text](#)
19. Jordheim LP, Durantel D, Zoulim F, *et al.*: **Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases**. *Nat Rev Drug Discov*. 2013; **12**(6): 447–64.
[PubMed Abstract](#) | [Publisher Full Text](#)
20. Retallack H, Di Lullo E, Arias C, *et al.*: **Zika Virus in the Human Placenta and Developing Brain: Cell Tropism and Drug Inhibition**. *bioRxiv*. 2016.
[Publisher Full Text](#)
21. Giguère JF, Tremblay MJ: **Statin compounds reduce human immunodeficiency virus type 1 replication by preventing the interaction between virion-associated host intercellular adhesion molecule 1 and its natural cell surface ligand LFA-1**. *J Virol*. 2004; **78**(21): 12062–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
22. Barrows NJ, Campos RK, Powell ST, *et al.*: **A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection**. *Cell Host Microbe*. 2016; **20**(2): 259–70.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
23. Mlakar J, Korva M, Tul N, *et al.*: **Zika Virus Associated with Microcephaly**. *N Engl J Med*. 2016; **374**(10): 951–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
24. Calvet G, Aguiar RS, Melo AS, *et al.*: **Detection and sequencing of Zika virus from amniotic fluid of fetuses with microcephaly in Brazil: a case study**. *Lancet Infect Dis*. 2016; **16**(6): 653–60.
[PubMed Abstract](#) | [Publisher Full Text](#)
25. Martines RB, Bhatnagar J, Keating MK, *et al.*: **Notes from the Field: Evidence of Zika Virus Infection in Brain and Placental Tissues from Two Congenitally Infected Newborns and Two Fetal Losses--Brazil, 2015**. *MMWR Morb Mortal Wkly Rep*. 2016; **65**(6): 159–60.
[PubMed Abstract](#) | [Publisher Full Text](#)
26. Sarno M, Sacramento GA, Khouri R, *et al.*: **Zika Virus Infection and Stillbirths: A Case of Hydrops Fetalis, Hydranencephaly and Fetal Demise**. *PLoS Negl Trop Dis*. 2016; **10**(2): e0004517.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
27. Miner JJ, Cao B, Govero J, *et al.*: **Zika Virus Infection during Pregnancy in Mice Causes Placental Damage and Fetal Demise**. *Cell*. 2016; **165**(5): 1081–91.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
28. Li C, Xu D, Ye Q, *et al.*: **Zika Virus Disrupts Neural Progenitor Development and Leads to Microcephaly in Mice**. *Cell Stem Cell*. 2016; **19**(1): 120–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
29. WHO: **Zika situation report**. 2016.
[Reference Source](#)
30. Xu M, Lee EM, Wen Z, *et al.*: **Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen**. *Nat Med*. 2016.
[PubMed Abstract](#) | [Publisher Full Text](#)
31. Whitehorn J, Nguyen CV, Khanh LP, *et al.*: **Lovastatin for the Treatment of Adult Patients With Dengue: A Randomized, Double-Blind, Placebo-Controlled Trial**. *Clin Infect Dis*. 2016; **62**(4): 468–76.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
32. Ikeda M, Abe K, Yamada M, *et al.*: **Different anti-HCV profiles of statins and their potential for combination therapy with interferon**. *Hepatology*. 2006; **44**(1): 117–25.
[PubMed Abstract](#) | [Publisher Full Text](#)
33. Rothwell C, Lebreton A, Young Ng C, *et al.*: **Cholesterol biosynthesis modulation regulates dengue viral replication**. *Virology*. 2009; **389**(1–2): 8–19.
[PubMed Abstract](#) | [Publisher Full Text](#)
34. Martínez-Gutiérrez M, Correa-Londoño LA, Castellanos JE, *et al.*: **Lovastatin delays infection and increases survival rates in AG129 mice infected with dengue virus serotype 2**. *PLoS One*. 2014; **9**(2): e87412.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
35. Sarkey JP, Richards MP, Stubbs EB Jr: **Lovastatin attenuates nerve injury in an animal model of Guillain-Barré syndrome**. *J Neurochem*. 2007; **100**(5): 1265–77.
[PubMed Abstract](#) | [Publisher Full Text](#)
36. Longley DB, Harkin DP, Johnston PG: **5-fluorouracil: mechanisms of action and clinical strategies**. *Nat Rev Cancer*. 2003; **3**(5): 330–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
37. Fischer MA, Smith JL, Shum D, *et al.*: **Flaviviruses are sensitive to inhibition of thymidine synthesis pathways**. *J Virol*. 2013; **87**(17): 9411–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
38. Shum D, Smith JL, Hirsch AJ, *et al.*: **High-content assay to identify inhibitors of dengue virus infection**. *Assay Drug Dev Technol*. 2010; **8**(5): 553–70.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
39. Slavik M, Elis J, Rašková H, *et al.*: **Therapeutic effects of 6-azauridine-triacetate in psoriasis**. *Pharmacol Clin*. 1970; **2**(2): 120–125.
[Publisher Full Text](#)
40. Rada B, Dragún M: **Antiviral action and selectivity of 6-azauridine**. *Ann N Y Acad Sci*. 1977; **284**: 410–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
41. Furuuchi T, Miura T, Kurihara K, *et al.*: **Design and synthesis of novel leucomycin analogues modified at the C-3 position. Part II: 3-O-(3-Aryl-2-propenyl)leucomycin analogues**. *Bioorg Med Chem*. 2008; **16**(8): 4401–18.
[PubMed Abstract](#) | [Publisher Full Text](#)
42. Kleber de Oliveira W, Cortez-Escalante J, De Oliveira WT, *et al.*: **Increase in Reported Prevalence of Microcephaly in Infants Born to Women Living in Areas with Confirmed Zika Virus Transmission During the First Trimester of Pregnancy - Brazil, 2015**. *MMWR Morb Mortal Wkly Rep*. 2016; **65**(9): 242–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
43. Karlis A, Berre S, Couderc T, *et al.*: **A human genome-wide loss-of-function screen identifies effective chikungunya antiviral drugs**. *Nat Commun*. 2016; **7**: 11320.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
44. Einarsen A, Maltepe C, Navioz Y, *et al.*: **The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparative study**. *BJOG*. 2004; **111**(9): 940–3.
[PubMed Abstract](#) | [Publisher Full Text](#)
45. Danielsson B, Wikner BN, Kallen B: **Use of ondansetron during pregnancy and congenital malformations in the infant**. *Reprod Toxicol*. 2014; **50**: 134–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
46. Pascoalino B, Courtemance G, Cordeiro M, *et al.*: **Dataset 1 in: Zika antiviral chemotherapy: identification of drugs and promising starting points for drug discovery from a FDA-approved library**. *F1000Research*. 2016.
[Data Source](#)

Open Peer Review

Current Peer Review Status:

Version 1

Reviewer Report 15 November 2016

<https://doi.org/10.5256/f1000research.10396.r17530>

© 2016 von Geldern T. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Tom von Geldern

Embedded Consulting, Illinois, IL, USA

Infection by Zika virus (ZIKV) is an emerging global health crisis, and as of today there are no approved therapeutic interventions available for patients. In a search for novel anti-ZIKV agents which could be moved quickly into clinical use, the authors have applied their well-established high-throughput, high-content assay platform to develop a ZIKV assay, and have applied this to evaluate a library of FDA-approved drugs. Building a high-quality high-content assay is a complex exercise, but this team is quite experienced, and has had particular success in the past with other tropical infectious agents.

Starting from a library of 725 compounds, a series of staged triage steps leads to the identification of 5 validated hits. While the established mechanisms for the majority of these hits (anti-cancer, antibiotic) are recognized sources of anti-parasitic leads, two are quite unexpected. Because they have been sourced from a collection of approved drugs, all should be able to move rapidly into in vivo proof-of-concept studies. Additionally, they might serve as starting points for further optimization by drug discovery teams; the sharing of these lead structures is a particularly altruistic decision on the part of the team.

The work reported here is very similar to that reported recently by another multi-national, multi-disciplinary consortium¹, who screened a nearly-identical collection in a similar manner. Interestingly, there was very little overlap in the hit-sets identified by these two teams. The origin of this difference is unclear, though the two groups used ZIKV from different sources; this may suggest that anti-viral activity is strain-dependent, complicating the development of agents with broad-based activity. It would be very interesting to have each team cross-test the other's set of leads in their own assay format.

References

1. Barrows NJ, Campos RK, Powell ST, Prasanth KR, et al.: A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection. *Cell Host Microbe*. 2016; **20** (2): 259-70 [PubMed Abstract](#) | [Publisher Full Text](#)

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 26 October 2016

<https://doi.org/10.5256/f1000research.10396.r17012>

© 2016 Anderson P. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Paul S Anderson

Independent Pharmaceuticals Professional, Lansdale, PA, USA

The authors describe a cell based assay suitable for screening compounds for activity against Zika virus. The assay is compatible with high content screening methodology and was used in this mode to screen a library of FDA-approved drugs. Palonosetron, 6-Azauridine, 5-Fluorouracil, Lovastatin and Kitasamycin were identified as low micromolar hits. The mechanism(s) for inhibition of the Zika virus infection was not identified.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research